These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 21188821)

  • 21. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system.
    Cohn JN
    J Appl Physiol (1985); 2010 Dec; 109(6):2006-7. PubMed ID: 21188834
    [No Abstract]   [Full Text] [Related]  

  • 22. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Activated intrarenal renin-angiotensin system is correlated with high blood pressure in humans.
    Kobori H; Fu Q; Crowley SD; Gonzalez-Villalobos RA; Campos RR
    J Appl Physiol (1985); 2010 Dec; 109(6):2003. PubMed ID: 21148352
    [No Abstract]   [Full Text] [Related]  

  • 23. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Intrarenal angiotensin II generation as a hypertensinogenic mechanism.
    Gonzalez-Villalobos RA; Fuchs S
    J Appl Physiol (1985); 2010 Dec; 109(6):2013. PubMed ID: 21188829
    [No Abstract]   [Full Text] [Related]  

  • 24. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Systemic hypertension--involvement of the CNS to this complex puzzle.
    Moreira TS; Takakura AC; Antunes VR
    J Appl Physiol (1985); 2010 Dec; 109(6):2004. PubMed ID: 21188814
    [No Abstract]   [Full Text] [Related]  

  • 25. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. AT1 receptors in the kidney mediate the chronic hypertensive response to angiotensin II.
    Crowley SD
    J Appl Physiol (1985); 2010 Dec; 109(6):2012-3. PubMed ID: 21188828
    [No Abstract]   [Full Text] [Related]  

  • 26. Counterpoint: Activation of the intrarenal renin-angiotensin system is the dominant contributor to systemic hypertension.
    Navar LG
    J Appl Physiol (1985); 2010 Dec; 109(6):1998-2000; discussion 2015. PubMed ID: 21148349
    [No Abstract]   [Full Text] [Related]  

  • 27. Point: Chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension.
    Esler M; Lambert E; Schlaich M
    J Appl Physiol (1985); 2010 Dec; 109(6):1996-8; discussion 2016. PubMed ID: 20185633
    [No Abstract]   [Full Text] [Related]  

  • 28. Electrical carotid baroreceptor stimulation.
    Schmidli J; von Allmen RS; Mohaupt MG
    Wien Med Wochenschr; 2014 Dec; 164(23-24):508-14. PubMed ID: 25411011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lowering of blood pressure by chronic suppression of central sympathetic outflow: insight from prolonged baroreflex activation.
    Lohmeier TE; Iliescu R
    J Appl Physiol (1985); 2012 Nov; 113(10):1652-8. PubMed ID: 22797307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rebuttal from Esler, Lambert, and Schlaich.
    Esler M; Lambert E; Schlaich M
    J Appl Physiol (1985); 2010 Dec; 109(6):2000-1. PubMed ID: 21148350
    [No Abstract]   [Full Text] [Related]  

  • 31. Rebuttal from Navar.
    Navar LG
    J Appl Physiol (1985); 2010 Dec; 109(6):2001-2. PubMed ID: 21148351
    [No Abstract]   [Full Text] [Related]  

  • 32. Endovascular Baroreflex Amplification for Resistant Hypertension.
    van Kleef MEAM; Bates MC; Spiering W
    Curr Hypertens Rep; 2018 May; 20(5):46. PubMed ID: 29744599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baroreflex control of sympathetic activity in experimental hypertension.
    Irigoyen MC; Krieger EM
    Braz J Med Biol Res; 1998 Sep; 31(9):1213-20. PubMed ID: 9876289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The sympathetic nervous system and hypertension: recent developments.
    DiBona GF
    Hypertension; 2004 Feb; 43(2):147-50. PubMed ID: 14707153
    [No Abstract]   [Full Text] [Related]  

  • 35. Role of the heart in blood pressure lowering during chronic baroreflex activation: insight from an in silico analysis.
    Clemmer JS; Pruett WA; Hester RL; Iliescu R; Lohmeier TE
    Am J Physiol Heart Circ Physiol; 2018 Nov; 315(5):H1368-H1382. PubMed ID: 30004810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sympathetic nervous system: role in hypertension and in chronic kidney disease.
    Grassi G; Bertoli S; Seravalle G
    Curr Opin Nephrol Hypertens; 2012 Jan; 21(1):46-51. PubMed ID: 22080859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New therapeutic approaches for resistant hypertension.
    Grassi G; Mancia G
    J Nephrol; 2012; 25(3):276-81. PubMed ID: 22362551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms mediating renal sympathetic nerve activation in obesity-related hypertension.
    Chen W; Leo S; Weng C; Yang X; Wu Y; Tang X
    Herz; 2015 Apr; 40 Suppl 2():190-6. PubMed ID: 24609799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence for a critical role of the sympathetic nervous system in hypertension.
    Grassi G; Ram VS
    J Am Soc Hypertens; 2016 May; 10(5):457-66. PubMed ID: 27052349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The interplay between sympathetic overactivity, hypertension and heart rate variability (review, invited).
    Drenjancevic I; Grizelj I; Harsanji-Drenjancevic I; Cavka A; Selthofer-Relatic K
    Acta Physiol Hung; 2014 Jun; 101(2):129-42. PubMed ID: 24901074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.